Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies

Basil T Darras, Claudia A Chiriboga, Susan T Iannaccone, Kathryn J Swoboda, Jacqueline Montes, Laurence Mignon, Shuting Xia, C Frank Bennett, Kathie M Bishop, Jeremy M Shefner, Allison M Green, Peng Sun, Ishir Bhan, Sarah Gheuens, Eugene Schneider, Wildon Farwell, Darryl C De Vivo, ISIS-396443-CS2/ISIS-396443-CS12 Study Groups, Basil T Darras, Claudia A Chiriboga, Susan T Iannaccone, Kathryn J Swoboda, Jacqueline Montes, Laurence Mignon, Shuting Xia, C Frank Bennett, Kathie M Bishop, Jeremy M Shefner, Allison M Green, Peng Sun, Ishir Bhan, Sarah Gheuens, Eugene Schneider, Wildon Farwell, Darryl C De Vivo, ISIS-396443-CS2/ISIS-396443-CS12 Study Groups

Abstract

Objective: To report results of intrathecal nusinersen in children with later-onset spinal muscular atrophy (SMA).

Methods: Analyses included children from a phase 1b/2a study (ISIS-396443-CS2; NCT01703988) who first received nusinersen during that study and were eligible to continue treatment in the extension study (ISIS-396443-CS12; NCT02052791). The phase 1b/2a study was a 253-day, ascending dose (3, 6, 9, 12 mg), multiple-dose, open-label, multicenter study that enrolled children with SMA aged 2-15 years. The extension study was a 715-day, single-dose level (12 mg) study. Time between studies varied by participant (196-413 days). Assessments included the Hammersmith Functional Motor Scale-Expanded (HFMSE), Upper Limb Module (ULM), 6-Minute Walk Test (6MWT), compound muscle action potential (CMAP), and quantitative multipoint incremental motor unit number estimation. Safety also was assessed.

Results: Twenty-eight children were included (SMA type II, n = 11; SMA type III, n = 17). Mean HFMSE scores, ULM scores, and 6MWT distances improved by the day 1,150 visit (HFMSE: SMA type II, +10.8 points; SMA type III, +1.8 points; ULM: SMA type II, +4.0 points; 6MWT: SMA type III, +92.0 meters). Mean CMAP values remained relatively stable. No children discontinued treatment due to adverse events.

Conclusions: Nusinersen treatment over ∼3 years resulted in motor function improvements and disease activity stabilization not observed in natural history cohorts. These results document the long-term benefit of nusinersen in later-onset SMA, including SMA type III.

Clinicaltrialsgov identifier: NCT01703988 (ISIS-396443-CS2); NCT02052791 (ISIS-396443-CS12).

Classification of evidence: This study provides Class IV evidence that nusinersen improves motor function in children with later-onset SMA.

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure 1. CS2 (phase 1b/2a open-label) and…
Figure 1. CS2 (phase 1b/2a open-label) and CS12 (extension) study designs and patient disposition
(A) Study designs: aOverall enrollment. bPatients received treatment on days 1 and 85 only. (B) Patient disposition: The CS2-CS12 integrated efficacy analysis included 28 children from CS2 who received their first dose of nusinersen in CS2 and could have been treated in CS12. The total number of nusinersen doses administered in CS2 was 2 (cohort 3) or 3 (cohorts 1, 2, and 4), and the total number of nusinersen doses administered in CS12 was 4. D = day; SMA = spinal muscular atrophy.
Figure 2. Mean change from baseline in…
Figure 2. Mean change from baseline in Hammersmith Functional Motor Scale–Expanded (HFMSE) score
Due to the gap between CS2 and CS12 and windowing of visit days, some windowed visits do not contain all children. SE = standard error; SMA = spinal muscular atrophy.
Figure 3. Mean change from baseline in…
Figure 3. Mean change from baseline in Upper Limb Module (ULM) score and 6-Minute Walk Test (6MWT) distance
(A) ULM: Assessed only in nonambulant participants. (B) 6MWT: Assessed only in ambulant participants. Due to the gap between CS2 and CS12 and windowing of visit days, some windowed visits do not contain all children. SE = standard error.
Figure 4. Mean change from baseline in…
Figure 4. Mean change from baseline in compound muscle action potential (CMAP) amplitude, CMAP area, and motor unit number estimation (MUNE) value
(A) CMAP amplitude, (B) CMAP area, and (C) MUNE value. Due to the gap between CS2 and CS12 and windowing of visit days, some windowed visits do not contain all children. SE = standard error; SMA = spinal muscular atrophy.

References

    1. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008;371:2120–2133.
    1. Darras BT, Markowitz JA, Monani UR, De Vivo DC. Spinal muscular atrophies. In: Darras BT, Royden Jones H Jr, Ryan MM, De Vivo DC, eds. Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, 2nd ed. San Diego: Academic Press; 2015:117–145.
    1. Hua Y, Sahashi K, Hung G, et al. . Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010;24:1634–1644.
    1. Finkel RS, Mercuri E, Darras BT, et al. . Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377:1723–1732.
    1. Finkel RS, Chiriboga CA, Vajsar J, et al. . Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016;388:3017–3026.
    1. De Vivo DC, Hwu W-L, Reyna SP, et al. . Interim efficacy and safety results from the phase 2 NURTURE study evaluating nusinersen in presymptomatic infants with spinal muscular atrophy. In: 69th Annual Meeting of the American Academy of Neurology; April 22–28, 2017; Boston.
    1. Mercuri E, Darras BT, Chiriboga CA, et al. . Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018;378:625–635.
    1. Finkel R, Bertini E, Muntoni F, Mercuri E. 209th ENMC International Workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7–9 November 2014, Heemskerk, The Netherlands. Neuromuscul Disord 2015;25:593–602.
    1. Glanzman AM, O'Hagen JM, McDermott MP, et al. . Validation of the expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol 2011;26:1499–1507.
    1. Pera MC, Coratti G, Forcina N, et al. . Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol 2017;17:39.
    1. Mazzone E, Bianco F, Martinelli D, et al. . Assessing upper limb function in nonambulant SMA patients: development of a new module. Neuromuscul Disord 2011;21:406–412.
    1. Montes J, McDermott MP, Martens WB, et al. . Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology 2010;74:833–838.
    1. Dunaway Young S, Montes J, Kramer SS, et al. . Six-Minute Walk Test is reliable and valid in spinal muscular atrophy. Muscle Nerve 2016;54:836–842.
    1. Lewelt A, Krosschell KJ, Scott C, et al. . Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve 2010;42:703–708.
    1. Kaufmann P, McDermott MP, Darras BT, et al. . Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 2012;79:1889–1897.
    1. Mazzone E, Bianco F, Main M, et al. . Six Minute Walk Test in type III spinal muscular atrophy: a 12 month longitudinal study. Neuromuscul Disord 2013;23:624–628.
    1. Sivo S, Mazzone E, Antonaci L, et al. . Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes. Neuromuscul Disord 2015;25:212–215.
    1. Swoboda KJ, Prior TW, Scott CB, et al. . Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 2005;57:704–712.
    1. Swoboda KJ, Scott CB, Crawford TO, et al. . SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One 2010;5:e12140.
    1. Chiriboga CA, Swoboda KJ, Darras BT, et al. . Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 2016;86:890–897.
    1. Mercuri E, Finkel R, Montes J, et al. . Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. Neuromuscul Disord 2016;26:126–131.
    1. Rouault F, Christie-Brown V, Broekgaarden R, et al. . Disease impact on general well-being and therapeutic expectations of European type II and type III spinal muscular atrophy patients. Neuromuscul Disord 2017;27:428–438.
    1. Shefner JM, Watson ML, Simionescu L, et al. . Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology 2011;77:235–241.
    1. Kang PB, Gooch CL, McDermott MP, et al. . The motor neuron response to SMN1 deficiency in spinal muscular atrophy. Muscle Nerve 2014;49:636–644.
    1. Kolb SJ, Coffey CS, Yankey JW, et al. . Natural history of infantile-onset spinal muscular atrophy. Ann Neurol 2017;82:883–891.
    1. Kang PB. Pediatric nerve conduction studies and EMG. In: Blum AS, Rutkove SB, eds. The Clinical Neurophysiology Primer. Totowa: Humana Press; 2007:369–389.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera